The North America Epigenetics Market would witness market growth of 14.0% CAGR during the forecast period (2022-2028).
In the context of this research, epigenetics refers to the study of genetic influences that are not wholly encoded by an organism's DNA sequence. Gene expression is the focus of epigenetics. In addition, Epigenetics also refers to functional alterations in the genome that do not involve a change in the nucleotide sequence. DNA methylation, also known as histone modification, is a form of epigenetic process.
Epigenetics is the study of heritable changes in gene function that do not involve changes in DNA sequence, such as chromosomal alterations, and are phenotypic in nature. Heritable alterations can be caused by external causes such as environmental influences or internal factors such as aging, sickness, and others. DNA methylation and histone modification are examples of epigenetics, which modify gene expression without changing the DNA sequence.
Cancer resistance to treatment is a huge stumbling block. Epigenetic medicines, alone or in combination with other treatments, may, nevertheless, be a feasible alternative. The epigenetic medication employed in the lab study renders the tumor vulnerable by preventing cancer cells from hiding from the immune system. As a result, the rising occurrence of cancer is predicted to boost the growth of the epigenetics market.
The rising cancer burden and increased spending on research and development activities are two major growth catalysts for the regional market. According to the American Cancer Society, 1.8 million new instances of cancer will be identified in the United States in 2020, with 606,520 people dying as a result. Cellular responses to apoptosis, cell proliferation, and senescence can all be influenced by epigenetic changes. The market for cardiovascular diseases is expected to increase steadily. Epigenetics has been found to play a key influence in cardiovascular illnesses in recent studies. Epigenetic information can aid in determining an individual's response to a medicine.
Additionally, it can be used to determine the risk factors for cardiovascular illnesses. As a result, it can be used to diagnose and predict cardiovascular illnesses. In the United States, heart disease is one of the major causes of death. According to the Centers for Disease Control and Prevention, one person in America dies from cardiovascular disease every 37 seconds.
The US market dominated the North America Epigenetics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $780.8 Million by 2028. The Canada market is anticipated to grow at a CAGR of 16.6% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 15.6% during (2022 - 2028).
Based on Application, the market is segmented into Oncology and Non-Oncology. Based on Product, the market is segmented into Kits, Reagents, Enzymes, and Instruments. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Epigenetics Market is Estimated to reach $2.9 Billion by 2028, at a CAGR of 14.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abcam plc, Agilent Technologies, Inc., Hologic, Inc., Illumina, Inc., Merck Group, PerkinElmer, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., Zymo Research, and Active Motif, Inc.
By Application
By Product
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
